China Dr Tianyi (Tee) Zhang, GM of Frontage China and SVP of Frontage Holdings, shares the significant growth of the China affiliate over the past four years; their competitive advantages in China with both bio-analytical and clinical services, their close collaborations with key hospitals, and their ‘Two Countries, One System’ philosophy…
France Francois Cornu, president of Eurofins Biomnis, and Gautier Decock, managing director of Eurofins BioPharma Product Testing in France and Belgium, come together to shed light on the company’s unique decentralized business model which incorporates CRO and diagnostic testing services. They go on to discuss the rationale behind this strategy and…
France Nathalie Giraud, director of integrated monitoring investigator services & head of France at PPD, breaks down the strengths and weaknesses of the French clinical trials environment and stresses the importance of France in PPD’s overall operations. She also explains how the contract research organization is catering to the needs of…
Croatia Lawyer Ira Perić Ostojić highlights recent regulatory updates in Croatia, where the legal status of cultivating and producing cannabis for medical purposes has been liberalised. On 25 April 2019 the Amendments to the Act on Combating Drugs Abuse entered into force in Croatia, which liberalizes the cultivation and production…
Croatia Lawyer Ira Perić Ostojić outlines two major new regulatory updates regarding pricing and reimbursement for drugs in Croatia. Bylaw regulating the maximum permitted wholesale price of the prescription medicinal products The bylaw regulates the detailed criteria for determining the maximum permitted wholesale price of prescription medicinal products in Croatia and…
China TJ Deng, GM China and BioDuro Discovery; and Ian Wisenberg, CFO of BioDuro, share the strategic rationale behind Advent International’s 2019 investment into the company; the focus of BioDuro 4.0 on growth, particularly in the US and Chinese markets; the differentiated and value-added services BioDuro can offer clients; and their…
China Amidst the sea of Big Pharma executives jumping ship to start highly regarded and attention-grabbing biotech companies, bolstered by the huge influx of capital, the opening of stock exchanges in first Hong Kong and subsequently Shanghai to pre-profit biotech companies that meet certain criteria, as well as the reformation and…
China Yan Hao, chairman and CEO of EPS Group shares the company’s journey to become Japan’s largest and most comprehensive provider of optimal outsourced solutions to the healthcare industry through its CRO, SMO and CSO operations. As CEO of EPS Group’s subsidiary company EPS China Group, Yan also outlines the China…
Spain Ian Wilders, managing director of Labo’Life, a Spanish micro-immunotherapy specialist, discusses the company’s history and the importance of regulatory reform in giving them greater market access and shifting the mindset of doctors. Furthermore, he touches on the company’s international strategy and the importance of a personalized care approach. Our…
France Bertrand Sohier, VP and general manager business and administration of Parexel France discusses the latest trends impacting the clinical research environment of the country, gives insight on the strategies the company utilizes to differentiate itself from competitors, and shares the importance of keeping a patient-focused mentality at the core of…
Spain Silvia Casellas, CEO of Anagram, a Spanish CRO, discusses the challenges of the consolidation process the company has gone in recent years, the reasons for the boom in Spain’s clinical trials ecosystem, and the importance of a close-knit client-to-service-provider relationship for CROs today. We are the first Spanish company…
China Dr Lingshi Tan, chairman and CEO of dMed, shares his strategic insights into the new era of Chinese biotech innovation and how it motivated him to leave Pfizer to establish dMed; the mission of dMed as ‘more than a CRO’ to support the growth of the Chinese biotech industry; their…
See our Cookie Privacy Policy Here